Skip to main content
Top
Published in: Trials 1/2014

Open Access 01-12-2014 | Research

Cross-sectional analysis of the reporting of continuous outcome measures and clinical significance of results in randomized trials of non-pharmacological interventions

Authors: Tammy C Hoffmann, Sarah T Thomas, Paul Ng Hung Shin, Paul P Glasziou

Published in: Trials | Issue 1/2014

Login to get access

Abstract

Background

Reporting the scoring details of continuous outcome measures in randomized trials allows readers to interpret the size of any effect of the intervention. This study aimed to determine, in a sample of randomized trials: 1) the completeness of reporting of scoring details for continuous outcome measures, and 2) whether trial authors comment on the clinical significance of statistically significant trial results.

Methods

A descriptive analysis of randomized trials of non-pharmacological interventions published during 2009 in the six leading general medical journals (n = 138), and which used at least one continuous outcome measure (n = 85). From each trial report, two authors independently extracted the following information about each continuous outcome measure: the reporting of its scoring details, presentation of its results, and the reporting and justification of the clinical significance of the results.

Results

Across the 84 trials, we identified 336 continuous outcome measures. A total of 146 (44%) were published measures, 12 (4%) were adapted from published measures, 5 (1%) were developed for the trial, and 173 (51%) were ‘conventional measures’ for which scoring details are not necessary (such as weight). For 57 (35%) of the 163 non-conventional outcome measures no scoring details or reference to the outcome measure were provided in the trial report. Of the 159 outcome measures with a statistically significant result, clinical significance was not mentioned for 81 (51%) and was reported without any elaboration or justification for 39 (25%) of them.

Conclusions

Scoring details of continuous outcome measures used in this sample of randomized trials of non-pharmacological interventions were incompletely reported, which hampers interpretation of a trial’s results. Complete reporting of scoring details is important when considering the clinical significance of the results. When deciding about an intervention, having this information may help clinicians in their conversations with patients about the possible benefits and harms, and their size, of the intervention.
Appendix
Available only for authorised users
Literature
1.
go back to reference Freiman JA, Chalmers TC, Smith H, Kuebler RR: The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 “negative” trials. New Eng J Med. 1978, 299: 690-694. 10.1056/NEJM197809282991304.CrossRefPubMed Freiman JA, Chalmers TC, Smith H, Kuebler RR: The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 “negative” trials. New Eng J Med. 1978, 299: 690-694. 10.1056/NEJM197809282991304.CrossRefPubMed
2.
go back to reference Savage DF: Reporting of continuous outcome measures in randomized clinical trials: is the whole story being told?. J Invest Med. 2010, 58: 106. Savage DF: Reporting of continuous outcome measures in randomized clinical trials: is the whole story being told?. J Invest Med. 2010, 58: 106.
3.
go back to reference Schriger DL, Savage DF, Altman DG: Presentation of continuous outcomes in randomised trials: an observational study. BMJ. 2012, 345: e8486-10.1136/bmj.e8486.CrossRefPubMedPubMedCentral Schriger DL, Savage DF, Altman DG: Presentation of continuous outcomes in randomised trials: an observational study. BMJ. 2012, 345: e8486-10.1136/bmj.e8486.CrossRefPubMedPubMedCentral
4.
go back to reference Baker GA, Hesdon B, Marson AG: Quality-of-life and behavioral outcome measures in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards. Epilepsia. 2000, 41: 1357-1363. 10.1111/j.1528-1157.2000.tb00110.x.CrossRefPubMed Baker GA, Hesdon B, Marson AG: Quality-of-life and behavioral outcome measures in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards. Epilepsia. 2000, 41: 1357-1363. 10.1111/j.1528-1157.2000.tb00110.x.CrossRefPubMed
5.
go back to reference Geyh S, Cieza A, Kollerits B, Grimby G, Stucki G: Content comparison of health-related quality of life measures used in stroke based on the international classification of functioning, disability and health (ICF): a systematic review. Qual Life Res. 2007, 16: 833-851. 10.1007/s11136-007-9174-8.CrossRefPubMed Geyh S, Cieza A, Kollerits B, Grimby G, Stucki G: Content comparison of health-related quality of life measures used in stroke based on the international classification of functioning, disability and health (ICF): a systematic review. Qual Life Res. 2007, 16: 833-851. 10.1007/s11136-007-9174-8.CrossRefPubMed
6.
go back to reference Hoffmann TC, Erueti C, Glasziou PP: Poor description of non-pharmacological interventions: analysis of consecutive sample of randomised trials. BMJ. 2013, 347: f3755-10.1136/bmj.f3755.CrossRefPubMedPubMedCentral Hoffmann TC, Erueti C, Glasziou PP: Poor description of non-pharmacological interventions: analysis of consecutive sample of randomised trials. BMJ. 2013, 347: f3755-10.1136/bmj.f3755.CrossRefPubMedPubMedCentral
7.
go back to reference Dobscha SK, Corson K, Perrin NA, Hanson GC, Leibowitz RQ, Doak MN, Dickinson KC, Sullivan MD, Gerrity MS: Collaborative care for chronic pain in primary care: a cluster randomized trial. JAMA. 2009, 301: 1242-1252. 10.1001/jama.2009.377.CrossRefPubMed Dobscha SK, Corson K, Perrin NA, Hanson GC, Leibowitz RQ, Doak MN, Dickinson KC, Sullivan MD, Gerrity MS: Collaborative care for chronic pain in primary care: a cluster randomized trial. JAMA. 2009, 301: 1242-1252. 10.1001/jama.2009.377.CrossRefPubMed
8.
go back to reference Wardlaw D, Cummings SR, Van Meirhaeghe J, Bastian L, Tillman JB, Ranstam J, Eastell R, Shabe P, Talmadge K, Boonen S: Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet. 2009, 373: 1016-1024. 10.1016/S0140-6736(09)60010-6.CrossRefPubMed Wardlaw D, Cummings SR, Van Meirhaeghe J, Bastian L, Tillman JB, Ranstam J, Eastell R, Shabe P, Talmadge K, Boonen S: Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet. 2009, 373: 1016-1024. 10.1016/S0140-6736(09)60010-6.CrossRefPubMed
9.
go back to reference Peron J, Pond GR, Gan HK, Chen EX, Almufti R, Maillet D, You B: Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. J Natl Cancer Inst. 2012, 104: 982-989. 10.1093/jnci/djs259.CrossRefPubMed Peron J, Pond GR, Gan HK, Chen EX, Almufti R, Maillet D, You B: Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. J Natl Cancer Inst. 2012, 104: 982-989. 10.1093/jnci/djs259.CrossRefPubMed
10.
go back to reference Chan KB, Man-Son-Hing M, Molnar FJ, Laupacis A: How well is the clinical importance of study results reported? An assessment of randomised controlled trials. CMAJ. 2001, 165: 1197-1202.PubMedPubMedCentral Chan KB, Man-Son-Hing M, Molnar FJ, Laupacis A: How well is the clinical importance of study results reported? An assessment of randomised controlled trials. CMAJ. 2001, 165: 1197-1202.PubMedPubMedCentral
11.
go back to reference Moher D, Dulberg CS, Wells GA: Statistical power, sample size, and their reporting in randomized controlled trials. JAMA. 1994, 272: 122-124. 10.1001/jama.1994.03520020048013.CrossRefPubMed Moher D, Dulberg CS, Wells GA: Statistical power, sample size, and their reporting in randomized controlled trials. JAMA. 1994, 272: 122-124. 10.1001/jama.1994.03520020048013.CrossRefPubMed
12.
go back to reference Molnar FJ, Man-Son-Hing M, Fergusson D: Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. J Am Geriatr Soc. 2009, 57: 536-546. 10.1111/j.1532-5415.2008.02122.x.CrossRefPubMed Molnar FJ, Man-Son-Hing M, Fergusson D: Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. J Am Geriatr Soc. 2009, 57: 536-546. 10.1111/j.1532-5415.2008.02122.x.CrossRefPubMed
13.
go back to reference Pocock SJ, Geller NL, Tsiatis AA: The analysis of multiple endpoints in clinical trials. Biometrics. 1987, 43: 487-498. 10.2307/2531989.CrossRefPubMed Pocock SJ, Geller NL, Tsiatis AA: The analysis of multiple endpoints in clinical trials. Biometrics. 1987, 43: 487-498. 10.2307/2531989.CrossRefPubMed
14.
go back to reference Chalmers I, Glasziou P: Avoidable waste in the production and reporting of research evidence. Lancet. 2009, 374: 86-89. 10.1016/S0140-6736(09)60329-9.CrossRefPubMed Chalmers I, Glasziou P: Avoidable waste in the production and reporting of research evidence. Lancet. 2009, 374: 86-89. 10.1016/S0140-6736(09)60329-9.CrossRefPubMed
15.
go back to reference Schulz KF, Altman DG, Moher D, Group C: CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010, 340: c332-10.1136/bmj.c332.CrossRefPubMedPubMedCentral Schulz KF, Altman DG, Moher D, Group C: CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010, 340: c332-10.1136/bmj.c332.CrossRefPubMedPubMedCentral
16.
go back to reference Altman DG, Moher D, Schulz KF: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001, 357: 1191-1194. 10.1016/S0140-6736(00)04337-3.CrossRefPubMed Altman DG, Moher D, Schulz KF: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001, 357: 1191-1194. 10.1016/S0140-6736(00)04337-3.CrossRefPubMed
17.
go back to reference Rothwell PM: Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials. 2006, 1: e9-10.1371/journal.pctr.0010009.CrossRefPubMedPubMedCentral Rothwell PM: Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials. 2006, 1: e9-10.1371/journal.pctr.0010009.CrossRefPubMedPubMedCentral
18.
go back to reference Beaton DE, Boers M, Wells GA: Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol. 2002, 14: 109-114. 10.1097/00002281-200203000-00006.CrossRefPubMed Beaton DE, Boers M, Wells GA: Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol. 2002, 14: 109-114. 10.1097/00002281-200203000-00006.CrossRefPubMed
19.
go back to reference Man-Son-Hing M, Laupacis A, O’Rourke K, Molnar FJ, Mahon J, Chan KY, Wells G: Determination of the clinical importance of study results. J Gen Intern Med. 2002, 17: 469-476. 10.1046/j.1525-1497.2002.11111.x.CrossRefPubMedPubMedCentral Man-Son-Hing M, Laupacis A, O’Rourke K, Molnar FJ, Mahon J, Chan KY, Wells G: Determination of the clinical importance of study results. J Gen Intern Med. 2002, 17: 469-476. 10.1046/j.1525-1497.2002.11111.x.CrossRefPubMedPubMedCentral
20.
go back to reference Beaton DE, Tarasuk V, Katz JN, Wright JG, Bombardier C: Are you better?” A qualitative study of the meaning of recovery. Arthritis Rheum. 2001, 45: 270-279. 10.1002/1529-0131(200106)45:3<270::AID-ART260>3.0.CO;2-T.CrossRefPubMed Beaton DE, Tarasuk V, Katz JN, Wright JG, Bombardier C: Are you better?” A qualitative study of the meaning of recovery. Arthritis Rheum. 2001, 45: 270-279. 10.1002/1529-0131(200106)45:3<270::AID-ART260>3.0.CO;2-T.CrossRefPubMed
21.
go back to reference McAlister RA, O’Connor A, Wells GA: When should hypertension be treated? The different perspectives of Canadian family physicians and patients. CAMJ. 2001, 164: 403-408. McAlister RA, O’Connor A, Wells GA: When should hypertension be treated? The different perspectives of Canadian family physicians and patients. CAMJ. 2001, 164: 403-408.
Metadata
Title
Cross-sectional analysis of the reporting of continuous outcome measures and clinical significance of results in randomized trials of non-pharmacological interventions
Authors
Tammy C Hoffmann
Sarah T Thomas
Paul Ng Hung Shin
Paul P Glasziou
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Trials / Issue 1/2014
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-15-362

Other articles of this Issue 1/2014

Trials 1/2014 Go to the issue